Core Viewpoint - Chinese listed companies are actively standardizing tax management to ensure compliance, with many companies undergoing self-inspections and identifying tax payment deficiencies, leading to significant tax arrears and penalties [1][2][3] Group 1: Tax Compliance and Self-Inspection - As of November 26, 2025, 63 A-share listed companies have announced the need to pay back corporate income tax and penalties, totaling approximately 2.8 billion yuan [1][3] - The company Tianxiaxiu reported a tax payment and penalty of 24.5157 million yuan due to misunderstandings of tax policy applicability [2][3] - Companies are taking proactive measures to correct historical tax issues, with some extending self-inspection periods back to five years [6][8] Group 2: Financial Impact - Tianxiaxiu's tax payment and penalty will reduce its net profit for 2025 by approximately 23.8413 million yuan, accounting for 46.30% of the latest audited net profit attributable to shareholders [3] - Shandong Gold announced a need to pay back 5.08 billion yuan in corporate income tax and 230 million yuan in penalties, totaling 7.38 billion yuan [8][9] - The actual tax amount paid by 5,091 listed companies in 2024 was approximately 39,727 billion yuan, representing about 22.7% of the national tax revenue [2] Group 3: Market Confidence and Economic Stability - Compliance with tax regulations is crucial for maintaining market confidence and economic stability, as tax payments directly affect national fiscal revenue [9] - Companies that rectify tax issues can mitigate operational risks associated with tax disputes, which may lead to cash flow disruptions and stock price volatility [9]

1. Report Industry Investment Rating - No relevant content provided 2. Core Viewpoints of the Report - On November 24, the liquidity was ample, with major repo rates hovering at low levels; the bond market showed a narrow - range oscillation; the convertible bond market's main indices followed the upward trend, and most convertible bond issues rose; yields on U.S. Treasuries of various maturities generally declined, and yields on 10 - year government bonds of major European economies generally decreased [1] 3. Summary by Relevant Catalogs 3.1 Bond Market News 3.1.1 Domestic News - President Xi Jinping had a phone call with U.S. President Trump, emphasizing that the Busan meeting had set the right course for China - U.S. relations, and both sides should maintain the positive momentum [3] - On November 25, the central bank conducted 100 billion yuan of MLF operations, with a net injection of 10 billion yuan in November, marking the ninth consecutive month of increased roll - overs, in line with market expectations [3] - As of November 21, the issuance of science - innovation bonds in the inter - bank market exceeded 530 billion yuan, with the proportion of issuance scale exceeding 10% for the first time, 5 percentage points higher than before [4] 3.1.2 International News - On November 24, Fed Governor Waller and San Francisco Fed President Daly signaled dovish stances, with Waller advocating a rate cut at the next meeting and Daly supporting a December rate cut [5][6] 3.1.3 Commodities - On November 24, international crude oil futures prices turned up, while international natural gas prices turned down. WTI January crude oil futures rose 1.34% to $58.84 per barrel, Brent January crude oil futures rose 1.29% to $63.37 per barrel, COMEX December gold futures rose 0.36% to $4094.2 per ounce, and NYMEX natural gas prices fell 1.55% to $4.506 per ounce [7] 3.2 Liquidity 3.2.1 Open Market Operations - On November 24, the central bank conducted 338.7 billion yuan of 7 - day reverse repurchase operations, with a net injection of 55.7 billion yuan as 283 billion yuan of reverse repurchases matured on the same day [9] 3.2.2 Funding Rates - On November 24, the liquidity was ample, with major repo rates hovering at low levels. DR001 dropped 0.22bp to 1.319%, and DR007 rose 2.95bp to 1.470% [10] 3.3 Bond Market Dynamics 3.3.1 Interest - rate Bonds - **Spot Bond Yield Trends**: On November 24, the bond market showed a narrow - range oscillation with lower trading volume. By 20:00, the yield of the 10 - year Treasury bond active issue 250016 dropped 0.05bp to 1.8120%, and the yield of the 10 - year CDB bond active issue 250215 remained flat at 1.8740% [13] - **Bond Tendering Results**: Information on the tendering of multiple bonds including 25贴现国债72, 25附息国债23, etc., was provided, covering details such as term, issuance scale, winning yield, and bid - to - cover ratios [14] 3.3.2 Credit Bonds - **Secondary - market Transaction Anomalies**: On November 24, no credit bond transaction prices deviated by more than 10% [15] - **Credit Bond Events**: Multiple companies such as Fanhai Holdings, Fangyuan Real Estate, and Baolong Industry had bond - related events including non - payment, extension of redemption dates, and holder meetings [16] 3.3.3 Convertible Bonds - **Equity and Convertible Bond Indices**: On November 24, the A - share market rose, with over 4200 stocks increasing. The Shanghai Composite Index, Shenzhen Component Index, and ChiNext Index rose 0.05%, 0.37%, and 0.31% respectively. The convertible bond market also rebounded, with the CSI Convertible Bond, Shanghai Convertible Bond, and Shenzhen Convertible Bond indices rising 0.22%, 0.14%, and 0.34% respectively [17] - **Convertible Bond Tracking**: News such as the approval of Shang Sheng Electronics' convertible bond issuance and the possible early redemption of Nenghui Convertible Bond were reported [24] 3.3.4 Overseas Bond Markets - **U.S. Treasury Market**: On November 24, yields on U.S. Treasuries of various maturities generally declined. The 2 - year U.S. Treasury yield dropped 5bp to 3.46%, and the 10 - year yield dropped 2bp to 4.04%. The 2/10 - year U.S. Treasury yield spread widened by 3bp to 58bp, and the 5/30 - year spread narrowed by 2bp to 107bp [20][21] - **European Bond Market**: On November 24, yields on 10 - year government bonds of major European economies generally declined, except for Germany and Spain where yields remained unchanged [23] - **Price Changes of Chinese - Issued U.S. Dollar Bonds**: Price changes of Chinese - issued U.S. dollar bonds of multiple companies such as Ctrip Group, Pinduoduo, and iQiyi were presented, including daily changes, credit entities, bond balances, and other information [25]

Group 1: Domestic News - President Xi Jinping and US President Trump had a phone call, emphasizing the importance of stable and positive Sino-US relations and the need for cooperation to benefit both nations and the world [2] - The People's Bank of China (PBOC) conducted a 1 trillion yuan MLF operation, marking the ninth consecutive month of increased net issuance, aligning with market expectations [2] Group 2: Bond Market Dynamics - The interbank market saw significant participation from private enterprises, with over 5.3 billion yuan in sci-tech bonds issued, representing more than 10% of the total issuance in the interbank market [3] - The bond market experienced narrow fluctuations, with the yield on the 10-year government bond slightly decreasing to 1.8120% [9] Group 3: Credit Bond Events - Several companies announced delays in bond repayments, including Fanghai Holdings, which postponed the repayment of approximately 3.56 billion USD in overseas notes until May 2026 [11] - Other companies, such as Fangyuan Real Estate and Xian Construction Group, also reported adjustments to repayment dates or overdue debts, indicating potential credit risks in the market [12][18] Group 4: Convertible Bonds - The convertible bond market saw a collective rise in major indices, with the market's trading volume increasing significantly to 618.80 billion yuan, indicating a rebound following previous declines [19] - Notable individual convertible bonds, such as Zhuomei Convertible Bond, experienced a surge of 57%, while others like Tianci Convertible Bond saw declines [19]

证券代码：600129 证券简称：太极集团 公告编号：2025-087 重庆太极实业（集团）股份有限公司 关于全资子公司破产清算的进展公告 本次法院受理破产申请，尚未指定破产管理人。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 重庆太极实业（集团）股份有限公司（以下简称：公司）全资子 公司内蒙古阿鲁科尔沁旗国太牧业有限公司（以下简称：国太牧业） 于近日收到内蒙古自治区阿鲁科尔沁旗人民法院（以下简称：科尔沁 法院）送达的《民事裁定书》（（2025）内 0421 破申 1 号），科尔 沁法院裁定受理国太牧业的破产申请。 一、国太牧业破产清算情况概述 公司于 2025 年 10 月 23 日召开第十届董事会第三十二次会议， 审议通过《关于全资子公司拟申请破产清算的议案》。由于市场竞争 及外部环境变化等因素，国太牧业经营业绩持续下滑，导致严重亏损， 资产已不足以偿付全部负债，为更好地聚焦主业发展，降低经营风险 和减少损失，维护公司及股东利益，公司董事会同意国太牧业向法院 申请破产清算。具体内容详见公司于 2025 年 10 月 ...

2020-2025年1-9月中国中成药产量统计图 数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 上市企业：云南白药（000538）,同仁堂（600085）,片仔癀（600436）,白云山（600332）,太极集团 （600129）,东阿阿胶（000423）,九芝堂（000989）,贵州百灵（002424）,葵花药业（002737）,吉林敖 东（000623） 相关报告：智研咨询发布的《2026-2032年中国中成药行业发展形势分析及产业前景规划报告》 根据国家统计局数据显示：2025年9月中国中成药产量为16.9万吨，同比增长2.4%；2025年1-9月中国中 成药累计产量为132.2万吨，累计下降8.3%。 ...

Core Viewpoint - The incidence of rhinitis in China is rising due to environmental changes and increased life stress, leading to a growing demand for rhinitis medications, particularly traditional Chinese medicine (TCM) products, which are favored for their convenience and fewer side effects. The sales of TCM rhinitis medications are projected to reach 3.27 billion yuan in 2024, representing a year-on-year growth of 12.06% [1][7]. Market Policy - The Chinese government has issued several policies to support the development of the TCM industry, including measures to enhance scientific regulation, promote innovation, and improve the quality of TCM products, creating a favorable environment for the growth of the TCM rhinitis medication sector [3][4]. Industry Chain - The upstream of the TCM rhinitis medication industry includes suppliers of traditional Chinese medicinal materials such as Cang'erzi, Xinyi, Baizhi, and Peppermint, as well as suppliers of pharmaceutical excipients and production equipment. The midstream consists of manufacturers of TCM rhinitis medications, while the downstream includes medical institutions, retail pharmacies, online pharmacies, and end consumers [5][6]. Development Status - The demand for rhinitis medications is increasing, with TCM products gaining popularity due to their ease of use and lower side effects. The market is seeing accelerated innovation and development, with new TCM products entering the market, such as Yiling Pharmaceutical's Qifang Nasal Tablets and Kangyuan Pharmaceutical's Suxin Tongqiao Granules [7][11]. Competitive Landscape - The market for TCM rhinitis medications in China is highly concentrated. In retail pharmacies, the top five companies (CR5) hold a market share of 57.27%, with Tai Chi Group having the largest share at 16.96%. In public medical institutions, the CR5 market share is even higher at 62.48%, with Lunan Pharmaceutical leading at 22.05% [8][9]. Industry Representative Companies - Lunan Pharmaceutical Group is a comprehensive pharmaceutical company with a strong presence in the TCM rhinitis medication market, particularly with its product Nasal Congestion Granules, which has seen significant sales growth. Tai Chi Group also plays a major role in the market, with a diverse product range and substantial revenue from both pharmaceutical manufacturing and commercial operations [10][11]. Development Trends - The future of TCM rhinitis medications will focus on clinical research to validate efficacy and safety through large-scale, multi-center, randomized controlled trials. There is also potential for TCM rhinitis medications to enter international markets, with companies expected to enhance international cooperation and adhere to global standards in research, production, and quality control [11][12].

Core Viewpoint - Taiji Group completed a share buyback on September 22, 2025, repurchasing 5.4726 million shares for a total expenditure of 120 million yuan, with the shares being canceled on September 24, 2025 [2] Summary by Category - **Share Buyback Details** - The company repurchased 5.4726 million shares [2] - Total funds used for the buyback amounted to 120 million yuan [2] - The cancellation of the repurchased shares was completed on September 24, 2025 [2] - **Changes in Capital Structure** - Following the buyback and cancellation, the total share capital decreased from 556,890,744.4 shares to 551,418,185 shares [2] - The registered capital changed from 556,890,744.4 yuan to 551,418,185 yuan [2]

Core Viewpoint - The company does not produce "Ganmaoling Granules" and clarifies its product offerings related to flu prevention and treatment [2]. Product Offerings - The company’s subsidiaries produce the following products: - Ganmao Qingre Granules - Ganmao Kousou Granules - Ganmao Zhike Granules - Sangju Ganmao Granules - Children's Ganmao Granules [2]. Flu Prevention and Treatment Products - The company’s main products for flu prevention and treatment include: - Huoxiang Zhengqi Oral Liquid - Lingyang Ganmao Granules/Tablets - Qingre Jiedu Oral Liquid - Children's Ganmao Granules - Compound Banlan Gen Granules - Refined Yinqiao Jiedu Tablets - Vitamin C Yinqiao Tablets - Compound Acetaminophen and Amantadine Capsules - Ankang Huangmin Tablets - Phenacetin and Acetaminophen Tablets - Chlorpheniramine and Acetaminophen Tablets - Compound Acetaminophen Tablets - Sustained-release Ibuprofen Tablets - Acetaminophen and Phenobarbital Injection - Compound Licorice Oral Solution - Compound Licorice Tablets - Meiyu Pseudoephedrine Oral Solution - Children's Acetaminophen and Chlorpheniramine Granules - Children's Acetaminophen, Caffeine Tablets [2].

Core Viewpoint - Taiji Group (600129.SH) currently does not produce Ganmaoling granules, but offers a variety of other cold and flu-related products [1] Product Offerings - The company produces the following products: - Ganmao Qingre granules - Ganmao Kousou granules - Ganmao Zhike granules - Sangju Ganmao granules - Children's Ganmao granules [1] Flu Prevention and Treatment - The company's main products for flu prevention and treatment include: - Huoxiang Zhengqi oral liquid - Lingyang Ganmao granules/tablets - Qingre Jiedu oral liquid - Children's Ganmao granules - Compound Banlan Gen granules - Refined Yin Qiao Jiedu tablets - Vitamin C Yin Qiao tablets - Compound Acetaminophen and Amantadine capsules - Ankang Huangmin tablets - Phenacetin and Acetaminophen tablets - Chlorpheniramine and Acetaminophen tablets - Compound Paracetamol tablets - Ibuprofen sustained-release tablets - Acetaminophen and Phenobarbital injection - Compound Glycyrrhiza oral solution - Compound Glycyrrhiza tablets - Meiyu Weima oral solution - Children's Acetaminophen and Huangnamin granules - Children's Acetaminophen, caffeine tablets [1]

Group 1 - The "10th Community Cultural Festival" concluded on November 15, celebrating its decade-long presence in the community [2] - The festival engaged 30 communities in Shandong, offering diverse themes and experiences for residents [2] - Eight communities received "Outstanding Cooperative Community" certificates, while eight companies, including Dong'e Ejiao Co., Ltd. and China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., were awarded "Strategic Cooperative Enterprise" certificates [2] Group 2 - The event featured cultural performances and community services, enhancing the well-being and happiness of residents [2] - The festival's growth was highlighted by the involvement of local enterprises, emphasizing their social responsibility [2] - Future initiatives include the "Ten Thousand People Learn First Aid Knowledge" program and the "Big Tree Plan" scholarship program for underprivileged students [2][3]